Indoco Remedies Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 15, 2010 to July 22, 2010 (both days inclusive) for the purpose of Payment of Dividend for the financial year 2009-10.

The Board of Directors of the Company at its meeting held on May 31, 2010, inter alia, recommended payment of divided of Rs. 7.00 per equity share i.e. 70% for financial year 2009-10 subject to the approval of members in the ensuing Annual General Meeting.

Indoco Remedies Ltd., a Mumbai-based
pharmaceutical company, announces the finalization of a generic product development
alliance with Watson Pharmaceuticals, Inc. to develop and manufacture a number of
sterile products for the United States market.

Under the terms of agreement, Indoco will develop, manufacture and supply a number
of products to Watson for the US market. The current US market size of these products
is US$ 679 million.

Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing
Director said, “This is a milestone deal for Indoco as out-licensing technology to a company
of Watson’s scale is a remarkable achievement. Watson Pharmaceuticals deal has the
potential to propel Indoco’s international business revenues to greater heights.”

Indoco is fully integrated to provide API manufacturing, formulation development and
manufacturing of the generic formulations for the selected products. Watson will
prepare and file the Abbreviated New Drug Applications (ANDAs) for US FDA
approval and will have rights to market, sell and distribute these products in the US
pharmaceutical market. For competitive reasons, details on the products to be
developed have not been disclosed.

As mutually agreed upon by both Watson and Indoco, development costs, including
bio-study / clinical trials costs, legal fees and net profits from the sale of these products
will be shared by Watson and Indoco in the agreed proportion.

Indoco will work together with Watson to explore the option of adding new products
and territories to this initial arrangement.

Indoco Remedies Ltd has informed BSE that the Board of Directors
of the Company at its meeting held on November 26, 2008, has
decided to declare an interim dividend of Rs 3.25 per share
(32.5%) for the financial year 2008-09.

Indoco Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 26, 2008, for the purpose of considering a proposal for declaration of an interim dividend for the financial year 2008-2009.

Indoco Remedies Ltd has informed
BSE that the Board of Directors of the Company at its meeting
held on September 05, 2008, inter alia, has confirmed the
proposal for recommendation of a dividend of Rs 5.00 per share
(50%) for the financial year ended March 31, 2008 (9 months).

Indoco Remedies Ltd has informed
BSE that the Board Meeting of the Company convened on September
02, 2008 for consideration of audited financial results and
declaration of divided, if any, has been adjourned, and the
adjourned meeting will be held on September 05, 2008 for
consideration of audited financial results and declaration of
dividend, if any, will be considered for the financial year ended
March 31, 2008.

Indoco Remedies Ltd has informed
BSE that a meeting of the Board of Directors of the Company will
be held on September 02, 2008, inter alia, for considering the
audited financial results for the financial year ended on March
31, 2008, and recommendation of dividend, if any, for the
financial year 2007- 2008.

Indoco Remedies Limited will have
March financial year ending from this fiscal. The Board of
Directors of Indoco Remedies Limited, which hitherto had a
financial year that ended in June, has decided to change its year
ending to March with immediate effect. Resultantly, its FY0708
will reflect the performance of a nine-month period ended March
31st, 2008.

Indoco Remedies Ltd has informed
BSE that the Board of Directors of the Company at its meeting
held on February 23, 2008, has approved the following:

1. Change of Company's financial year ending from June 30th to
March 31st. Consequently, the financial year of the Company for
2007-08 will be for a 9 months period from July 01, 2007 to March
31, 2008.

2. A Scheme of Amalgamation for a proposal to amalgamate
Company's 100% subsidiary, Shree Herbal Technologies Ltd., with
the Company.

Further the Company has informed that, the Board of Directors of
the Company has accepted the resignation of Mr. Atul S
Rajadhyaksha as Director w.e.f. February 23, 2008 and has
appointed Mr. Sharad P Upasani as the Director w.e.f. February
23, 2008 in the vacancy caused by the resignation of Mr. Atul S
Rajadhyaksha.

Indoco Remedies Ltd has informed
BSE that the Board of Directors of the Company at its meeting
held on January 29, 2008, has decided to take up 100% equity
stake in Shree Herbal Technologies Ltd (SHTL) for a consideration
of Rs 251.00 lacs. The investment will make SHTL a wholly owned
subsidiary of the Company.

SHTL is an unlisted Company with registered office at Delhi. It
was incorporated in 2005 and is yet to commence manufacturing
operations.

The Company will leverage its manufacturing capacity from the
investment.

Indoco
Remedies enters into a Joint Venture partnership with US based
company to launch Ophthalmics in US
October
18, 2007

Mumbai, October 18, 2007: Indoco
Remedies Limited and Amneal Pharmaceuticals, a New Jersey-based
developer, manufacturer and distributor of generic
pharmaceuticals announce the finalization of a joint venture
partnership to develop, manufacture, market and distribute
several products for the United States market. The initial
product pipeline will include at least ten ophthalmic products,
several of which have already progressed substantially through
the development process.

Under the terms of this agreement, the expertise of each company
will be leveraged to create a highly efficient and effective
product flow, from API manufacturing through regulatory approval
and distribution that will bring at least ten high-quality
generic drugs to the US market over the next five years. The
product selection committee, made up of three members from each
company, chose the first group of products to build a balanced
offering in the ophthalmic category, providing potential
customers a single source for the most important molecules of the
category.

Indoco’s responsibilities within the joint venture are, API
manufacturing for the majority of these products, formulation
development, analytical method development, production of
bioequivalence batches, data reporting and ultimately
manufacturing of the approved generic drugs for export to U.S.

Amneal’s role in the partnership is to prepare and file the ANDAs
for US FDA approval using the emerging eCTD/QBR/QOS process,
maintaining all required FDA and regulatory agency documentation
both prior to and following approval as well as to exclusively
sell, market and distribute these products throughout the US
pharmaceutical market across all segments.

With balanced input from both Amneal and Indoco, funding for
developing all these products, including bio-study costs, legal
fees and other development expenses, will be equally shared.
Likewise, the financial benefit from the sale of these products
will be shared.

For additional development after this initial group of products,
Indoco and Amneal have already begun to identify several more
products to pursue, in the ophthalmic category as well as other
therapeutic categories and dosage forms. The two companies fully
expect this agreement to expand significantly in the near term
and for it to last for many years.

In Amneal, Indoco now has a young and growing US generic company
as a partner to market their ophthalmic products in USA. This
partnership will help Indoco to speedily introduce their products
in the U.S. market and to explore other areas of growth
opportunities in the largest generic market of the world.

Mumbai, July 4, 2007: Indoco Remedies Ltd today announced that its solid dosage facility at Goa, Plant I has received approval from Brazilian food and drug agency,
ANVISA, marking the beginning of company’s foray into one of the largest pharmaceutical market in the world. This approval paves way for contract manufacturing opportunities for Indoco in Brazil.

Ms. Aditi Kare Panandikar, Director Business development said, "As
a part of companies growth strategy & to move up the value chain, Indoco Remedies intends to enter newer, semi-regulated and regulated markets worldwide after getting approvals from the respective regulatory authorities”.

In addition, Indoco Remedies is working towards obtaining MCC approvals, for their Solid dosage as well as Sterile Plants. Out of Company’s two manufacturing facilities at Goa, Plant I is approved by MHRA-UK, for Tablets, Cream & Capsules and by Darmstadt Germany for Solid Dosages. Plant II is a state-of-the-art sterile facility for Ophthalmics and Injectables approved by USFDA.